tiprankstipranks
Trending News
More News >
TMS Co., Ltd. (JP:4891)
:4891
Japanese Market

TMS Co., Ltd. (4891) Price & Analysis

Compare
1 Followers

4891 Stock Chart & Stats

¥129.00
-¥1.00(-0.47%)
At close: 4:00 PM EST
¥129.00
-¥1.00(-0.47%)

TMS Co., Ltd. News

4891 FAQ

What was TMS Co., Ltd.’s price range in the past 12 months?
TMS Co., Ltd. lowest stock price was ¥120.00 and its highest was ¥314.00 in the past 12 months.
    What is TMS Co., Ltd.’s market cap?
    TMS Co., Ltd.’s market cap is ¥7.05B.
      When is TMS Co., Ltd.’s upcoming earnings report date?
      TMS Co., Ltd.’s upcoming earnings report date is Feb 13, 2026 which is in 11 days.
        How were TMS Co., Ltd.’s earnings last quarter?
        Currently, no data Available
        Is TMS Co., Ltd. overvalued?
        According to Wall Street analysts TMS Co., Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does TMS Co., Ltd. pay dividends?
          TMS Co., Ltd. does not currently pay dividends.
          What is TMS Co., Ltd.’s EPS estimate?
          TMS Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does TMS Co., Ltd. have?
          TMS Co., Ltd. has 45,485,767 shares outstanding.
            What happened to TMS Co., Ltd.’s price movement after its last earnings report?
            Currently, no data Available
            Which hedge fund is a major shareholder of TMS Co., Ltd.?
            Currently, no hedge funds are holding shares in JP:4891
            What is the TipRanks Smart Score and how is it calculated?
            Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

              Company Description

              TMS Co., Ltd.

              TMS Co., Ltd. engages in the research and development, manufacture, and sale of drug products, quasi-drugs, drug substances, medical devices, and medical commodities. The company is developing TMS-007, a stachybotrys microspora triprenyl phenol (SMTP) congener with prothrombolytic and anti-inflammatory/antioxidative activities, which has completed Phase 2a clinical trials for acute ischemic stroke treatment; and TMS-008, an SMTP congener with anti-inflammatory/antioxidative activities under nonclinical development for inflammatory complications, such as acute kidney injury and cancer cachexia. It is also developing TMS-009, a product candidate in preclinical development. The company has a collaboration with Hokkaido University and Kanazawa University to evaluate the potential of the drug candidate compounds as novel drugs, as well as a joint research agreement with Teikyo University to identify biomarkers for renal function and a strategic alliance with Ji Xing Pharmaceuticals Limited. TMS Co., Ltd. was incorporated in 2005 and is headquartered in Fuchu, Japan.

              TMS Co., Ltd. (4891) Earnings & Revenues

              Similar Stocks
              Company
              Price & Change
              Follow
              OncoTherapy Science
              Linical Co., Ltd.
              MEDINET Co., Ltd.
              Cytori Cell Research Institute, Inc.
              Noile-Immune Biotech Inc.
              Popular Stocks